Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Microvascular Therapeutics LLC is currently engaged in the Biotechnology & Pharmaceuticals technology area. The company has 2 pending office actions that require a response from the legal team. Both of these matters are assigned to 1 distinct examiner, VU, JAKE MINH, who handles the entirety of the active workload. The prosecution is further concentrated within 1 distinct art unit.
VU, JAKE MINH is the busiest examiner for this portfolio, currently overseeing 2 pending office actions. This means that the company's current challenges at the patent office are being reviewed by a single individual. The lack of diversity in examiners or art units suggests that the company's technology is being evaluated through a very specific administrative lens within the Biotechnology & Pharmaceuticals sector.
For practitioners, having 2 pending office actions with 1 distinct examiner allows for a consistent prosecution strategy. However, it also means that the company's success is entirely dependent on the interpretations of VU, JAKE MINH. Because there is only 1 distinct art unit involved, there are no competing procedural styles to navigate, making the interaction with the assigned examiner the defining element of the portfolio's current status.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, JAKE MINH | 1 | 41.1% | +27.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18219656 | COMPOSITIONS AND METHODS OF DETECTING AND TREATING THROMBOSIS AND VASCULAR PLAQUES | VU, JAKE MINH | 154d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18219656 | COMPOSITIONS AND METHODS OF DETECTING AND TREATING THROMBOSIS AND VASCULAR PLAQUES | VU, JAKE MINH | 154d overdue |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18219656 | COMPOSITIONS AND METHODS OF DETECTING AND TREATING THROMBOSIS AND VASCULAR PLAQUES | VU, JAKE MINH | 1618 | §102§103Other | Final Rejection | 154d overdue | Pending | Jul 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial